Zhu AX, et al. - Investigators studied 292 eligible subjects aged 18 years or older to verify the effectiveness of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher between July 26, 2015 and August 30, 2017. They observed grade 3 or worse treatment-emergent adverse effects like hypertension, hyponatremia and increased aspartate aminotransferase in at least 5% of candidates. Conclusively, they noted improved overall survival in the ramucirumab group who had previously received sorafenib. They suggested ramucirumab is a well-tolerated regimen with a manageable safety profile.